Johnson & Johnson to Host Pharmaceuticals Business Review

NEW BRUNSWICK, N.J., April 23, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceuticals business for the Investment Community beginning at 8:30 a.m. (Eastern Time) on Thursday, May 23, 2013 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 3:00 p.m.

Paul Stoffels, M.D., Worldwide Chairman Pharmaceuticals, and Chief Scientific Officer and Joaquin Duato, Worldwide Chairman, Pharmaceuticals will host the meeting. The meeting will also feature presentations from the therapeutic area leaders within the Pharmaceuticals Research and Development organization.

The agenda for the day will be posted on the Investor Relations website on approximately May 16th.

Investors and other interested parties may access this meeting by visiting the Company's website at www.investor.jnj.com for a simultaneous webcast of the presentations. 

A replay and podcast will be available shortly after the live webcast through www.investor.jnj.com.

SOURCE Johnson & Johnson

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.